Prospects for the development of novel anti-hyperlipidemic drugs

Giuseppe Derosa, Sibilla Salvadeo, Arrigo F G Cicero

Research output: Contribution to journalArticlepeer-review


Hyperlipidemia is a well-established risk factor for atherogenesis and cardiovascular disease. Statins have been the cornerstone of treatment for hyperlipidemia in recent years and have significantly contributed to the improvement of cardiovascular disease therapy. However, novel antihyperlipidemic agents that have been developed over the last decade possess the capacity to significantly reduce plasma lipoproteins. This review analyzes the pharmacological profile, effectiveness and safehj of some promising drugs that are either already in clinical use (eg, ezetimibe and nicotinic acid) or under study (eg, acyl-CoA cholesterol acyltransferase inhibitors, cholesteryl ester transfer protein inhibitors and apolipoprotein A-IMilano).

Original languageEnglish
Pages (from-to)826-833
Number of pages8
JournalCurrent Opinion in Investigational Drugs
Issue number9
Publication statusPublished - Sep 2006


  • Acyl-CoA cholesterol acyltransferase inhibitors
  • Apolipoprotein A-I
  • Atherosclerosis
  • Cholesteryl ester transfer protein inhibitors
  • Dyslipidemia
  • Ezetimibe
  • Microsomal triglyceride transfer protein inhibitors
  • Nicotinic acid

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Prospects for the development of novel anti-hyperlipidemic drugs'. Together they form a unique fingerprint.

Cite this